BioNTech SE
BNTX
Company Profile
Business description
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Contact
An der Goldgrube 12
MainzRPD-55131
DEUT: +49 613190840
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
6,133
BioNTech SE News & Analysis
stocks
COVID-19 vaccine booster plans match our expectations
We don’t expect any changes to our fair value estimates or moat ratings for the mRNA manufacturers.
stocks
Waiving vaccine IP doesn't affect market assessment: Morningstar
We are not changing our fair values to COVID-19 vaccine firms following the proposed waiver on intellectual property protection.
stocks
Should you invest in the vaccine makers?
Demand for covid-19 vaccines has seen interest in pharma stocks soar, but Morningstar analysts think this is a temporary trend.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.10 | 50.10 | -0.58% |
| CAC 40 | 7,198.45 | 31.19 | -0.43% |
| DAX 40 | 19,004.78 | 55.53 | -0.29% |
| Dow JONES (US) | 43,290.65 | 21.71 | 0.05% |
| FTSE 100 | 8,085.07 | 13.95 | -0.17% |
| HKSE | 19,705.01 | 41.34 | 0.21% |
| NASDAQ | 18,871.27 | 116.20 | -0.61% |
| Nikkei 225 | 38,352.34 | 62.09 | -0.16% |
| NZX 50 Index | 12,737.06 | 79.26 | -0.62% |
| S&P 500 | 5,895.37 | 21.61 | -0.37% |
| S&P/ASX 200 | 8,326.30 | 47.70 | -0.57% |
| SSE Composite Index | 3,367.99 | 21.98 | 0.66% |